Tempus AI Inc (NASDAQ: TEM) (FRA: F3M) has partnered with Median Technologies SA (EPA: ALMDT) (FRA: 4ZG) to bring advanced AI lung cancer screening directly into clinical practice.
On Feb. 12, the Chicago-based precision medicine company announced it will integrate Median’s eyonis Lung Cancer Screening (LCS) software as a medical device into the Tempus Pixel platform — an AI-powered radiology imaging solution. Radiologists and care teams now access a single-step AI tool that detects lung nodules on low-dose CT scans, characterizes them and assigns a proprietary malignancy score to classify risk and prioritize patients.
The collaboration addresses a major gap in U.S. lung cancer screening. Only 20 per cent of eligible individuals currently participate yet experts say full adoption could prevent 62,110 deaths over five years, according to research published by the Journal of the American Medical Association.
eyonis LCS delivers 93.3 per cent sensitivity, 92.4 per cent specificity and 99.9 per cent negative predictive value, helping clinicians identify suspicious findings earlier while reducing unnecessary follow-ups and streamlining workflows.
Analysts at Simply Wall St have noted that the move deepens Tempus’s role across radiology and pathology, building on its acquisitions of Arterys for imaging tools and Paige for large-scale collections of labeled tissue slide images.
Median CEO Fredrik Brag calls the deal “a decisive step in bringing eyonis LCS to patients at national scale,” crediting Tempus’s AI leadership and broad market presence. Furthermore, Tempus General Manager of AI Products Razik Yousfi stresses that “AI reaches its full potential when it helps clinicians identify disease earlier and more accurately.”
The integration positions Tempus alongside major players like GE HealthCare Technologies Inc (NASDAQ: GEHC) and Siemens AG (OTCMKTS: SIEGY) (FRA: SIE) in AI-enhanced decision support for hospitals, biopharma and insurance providers.
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Regulatory progress drives AI innovation in lung screening
This partnership directly builds on eyonis LCS receiving FDA 510(k) clearance on Feb. 9. This special designation confirms the AI software meets safety and effectiveness standards by demonstrating substantial equivalence to predicate (previously approved) devices. It unlocks significant commercialization potential.
This progress echoes breakthroughs at peers such as Breath Diagnostics, which on Feb. 19 secured FDA Breakthrough Device Designation for its OneBreath platform.
Both companies pioneer lung screening tech that harnesses AI. Tempus and Median do so through imaging-based nodule risk assessment. Breath Diagnostics employs it to assist with rapid molecular breath analysis for pre-operative pneumonia risk and lung cancer screening.
These medtech innovators are delivering non-invasive, high-precision tools that drive earlier interventions and better patient outcomes. Advancements like these accelerate AI adoption in lung care, promising higher screening participation, fewer missed diagnoses and stronger clinical results for millions at risk.
Read more: Prestigious medtech intelligence firm recognizes Breath Diagnostics for innovation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
